Accesswire
12 Aug 2026, 12:45 UTC · 2h ago
Lobe Sciences Ltd. Announces Non-Brokered Private Placement
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Accesswire
12 Aug 2026, 12:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Lobe Sciences is conducting a non-brokered private placement of 24,705,880 common shares at $0.085 per share. — The issuance of a large volume of new shares creates immediate equity dilution for existing shareholders.
-0.40The private placement will generate approximately $2.1 million in aggregate gross proceeds. — Increased cash reserves provide a necessary runway for clinical development and working capital.
+0.20Proceeds will specifically fund the clinical development of the S-100 molecule for sickle cell disease via subsidiary Applied Lipid Technology. — Directs capital toward a specific lead asset, potentially accelerating a value-driving clinical milestone.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is raising approximately $2.1 million through a private placement to fund cash reserves and clinical development.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
